Blau Farmacêutica S.A. (BVMF:BLAU3)
Brazil
· Delayed Price · Currency is BRL | Market Cap | 2.36B |
| Revenue (ttm) | 1.70B |
| Net Income (ttm) | 294.96M |
| Shares Out | 230.98M |
| EPS (ttm) | 1.28 |
| PE Ratio | 8.01 |
| Forward PE | 7.73 |
| Dividend | 0.36 (3.47%) |
| Ex-Dividend Date | Mar 24, 2026 |
| Volume | 209,400 |
| Average Volume | 294,865 |
| Open | 10.11 |
| Previous Close | 10.23 |
| Day's Range | 9.96 - 10.23 |
| 52-Week Range | 8.72 - 11.84 |
| Beta | 0.38 |
| RSI | 38.26 |
| Earnings Date | May 13, 2026 |
About Blau Farmacêutica
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics... [Read more]
Financial Performance
In 2025, Blau Farmacêutica's revenue was 1.70 billion, a decrease of -2.96% compared to the previous year's 1.75 billion. Earnings were 294.96 million, an increase of 35.80%.
Financial StatementsNews
Blau Farmacêutica Earnings Call Transcript: Q4 2025
2025 saw strategic divestment, record investments in biotech, and improved margins despite a 3% revenue drop. Net income rose 39%, and new launches plus expanded capacity set the stage for stronger, less volatile growth in 2026.
Blau Farmacêutica Earnings Call Transcript: Q3 2025
Revenue and gross margin remained strong, with net income up 52% year-over-year. Capacity constraints limited growth, but major expansions and new product launches are set to drive a 70% increase in production and 60% growth in launches over the next three years.
Blau Farmacêutica Earnings Call Transcript: Q2 2025
Revenue remained stable year-over-year amid capacity constraints, but gross margin and EBITDA reached post-pandemic highs. New production lines, a strong pipeline, and the Prothya exit position the company for accelerated growth and strategic investments.
Blau Farmacêutica Earnings Call Transcript: Q1 2025
Revenue grew 4% year-over-year in Q1 2025, with strong 15% growth in the private hospital segment and a 50% increase in net income. Investments in biotechnology and new product launches support a robust outlook, despite temporary impacts from regulatory and supply chain transitions.
Blau Farmacêutica Earnings Call Transcript: Q3 2024
Achieved record quarterly revenue of BRL 474 million, up 31% year-over-year, with strong growth in the hospital segment and improved margins. R&D investment remained high, and integration of Bergamo advanced, while focus shifted to private market sales and Latin American expansion.
Blau Farmacêutica Earnings Call Transcript: Q2 2024
Q2 2024 saw record revenue and margin expansion, driven by strong private market growth, new product launches, and operational efficiencies. Strategic investments in R&D, capacity, and partnerships position the company for continued growth, with robust cash and low leverage.